NCT03823911View on ClinicalTrials.gov

Cardiovascular Disease in HIV and Hepatitis C: Risk Outcomes After Hepatitis C Eradication

PHASE4CompletedINTERVENTIONAL
Enrollment

87

Participants

Timeline

Start Date

November 18, 2018

Primary Completion Date

December 31, 2022

Study Completion Date

December 31, 2022

Conditions
Cardiovascular DiseasesHepatitis CHiv
Interventions
DRUG

Elbasvir / Grazoprevir Oral Tablet [Zepatier]

All approved direct-acting antivirals for hepatitis C will be used as the intervention.

PROCEDURE

Cardiac MRI

Cardiac MRI to assess for myocardial function and fibrosis

Trial Locations (2)

20019

Unity Parkside Health Center, Washington D.C.

21201

Institute of Human Virology, CRU, Baltimore

All Listed Sponsors
collaborator

National Institutes of Health (NIH)

NIH

collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

University of Maryland, Baltimore

OTHER

NCT03823911 - Cardiovascular Disease in HIV and Hepatitis C: Risk Outcomes After Hepatitis C Eradication | Biotech Hunter | Biotech Hunter